-
Two major CAR-T therapies "topped" NEJM, but one is happy and the other is worried about tumor information
Time of Update: 2022-03-06
In this international phase III trial, patients with relapsed or refractory LBCL within 12 months of first-line chemoimmunotherapy were randomly assigned (1:1) to receive axi-cel or standard therapy (using investigator's choice of , two or three cycles of chemoimmunotherapy, and high-dose chemotherapy and autologous stem cell transplantation for responding patients) .
-
Liver Cancer: Response to Lenvatinib (Lenvatinib) Initial Treatment is a Prognostic Indicator for Lenvatinib (LEN) + Transarterial Chemoembolization (LEN-TACE) Sequential Therapy
Time of Update: 2022-03-05
Therefore, a study was recently published in the journal Liver Cancer, mainly to compare the efficacy and safety of LEN-TRAE sequential therapy with LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC), and to explore the impact Factors of deep response to LEN-TRAE sequential therapy .
-
Interpretation of the update points of "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer 2021"
Time of Update: 2022-03-05
The Chinese Society of Clinical Oncology (CSCO) updates the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer" every year based on the latest research progress .
-
Science Advances: mRNA technology enters new field: used to treat fractures and bone defects, promote bone regeneration
Time of Update: 2022-03-05
Recently, researchers from the Mayo Clinic in the United States published a research paper entitled: Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2 in the journal Science Advances .
-
Target Oncol: Real-world evaluation of the efficacy and safety of abiraterone plus prednisone or prednisolone (AAP) in first- or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
Time of Update: 2022-03-05
Recently, Targeted Oncology published data from a real-world study evaluating the safety and efficacy of AAP as a first- and second-line [post-docetaxel (AAP-PD) only] treatment of patients with mCRPC .
-
How to pathologically evaluate the efficacy of neoadjuvant therapy for lung cancer?
Time of Update: 2022-03-05
To provide a reliable basis for further clinical treatment and prognosis prediction, pathologists and clinicians jointly formulated the "Expert Consensus on Pathological Evaluation of the Efficacy of Neoadjuvant Therapy for Non-Small Cell Lung Cancer (NSCLC) (2021 Edition)" .
-
Gastric Cancer: Aspirin and long-term survival after gastric adenocarcinoma surgery
Time of Update: 2022-03-05
Studies have shown that low-dose aspirin use may reduce cancer morbidity and mortality, but its effect on survival in gastric adenocarcinoma is unclear .
A foreign team conducted a related study to evaluate whether taking aspirin after gastrectomy for gastric adenocarcinoma could improve long-term survival .
-
BMC Cancer: Evaluating the efficacy of a weekly low-dose bevacizumab combination regimen in patients with platinum-resistant ovarian cancer
Time of Update: 2022-03-05
In conclusion, the study shows that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, which needs further verification in the future .
-
J Clin Oncol: The Impact of Anti-Racist Interventions on Racial Disparities in Lung Cancer Surgery
Time of Update: 2022-03-05
In conclusion, the study shows that anti-racism interventions are associated with promoting timely surgery in patients with early-stage lung cancer, helping to reduce racial disparities in timely surgery .
-
Eur Urol: Association between age, prostate cancer risk and higher Gleason score in a long-term screening program
Time of Update: 2022-03-05
Diagnostic ScreeningPrevious studies have suggested a possible association between older age, increased risk of prostate cancer (PC), and higher Gleason scores .
The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the G ö teborg-1 Prostate Cancer Screening Trial .
-
Hepatology: Dynamic risk prediction of recurrence after radical hepatectomy for hepatocellular carcinoma
Time of Update: 2022-03-05
Compared to single-event time-to-event estimates, multi-state modeling provides more realistic predictions of clinical outcomes after hepatectomy for patients with hepatocellular carcinoma by accounting for multiple postoperative disease states and transitions between them.
-
Clinical trial of CAR-T cell therapy ATA2271 suspended due to patient death
Time of Update: 2022-03-05
CAR-TThe MSK Phase I clinical study enrolled 27 patients, 25 with malignant pleural mesothelioma (MPM), 1 with metastatic lung cancer , and 1 with metastatic breast cancer , who had received 3 prior treatment regimens , The purpose of this study was to evaluate the safety and potential antitumor activity of mesothelin-targeted autologous CAR-T cell therapy .
-
2022 EANM Guidelines: Intraarterial Radioactive Compounds for the Treatment of Liver and Metastatic Liver Cancers
Time of Update: 2022-03-05
In February 2022, the European Association for Nuclear Medicine (EANM) published guidelines for the treatment of liver and metastatic liver cancer with intra-arterial radioactive compounds .
Primary liver cancer is one of the most common cancers worldwide, yet only 10%-20% of patients can receive treatment .
-
Cancer Treat Rev: Immune pk chemotherapy, first-line treatment for advanced urothelial carcinoma
Time of Update: 2022-03-05
Overall survival with IO vs chemotherapy in cisplatin-intolerant patientsPatients who could not be treated with cisplatin also had comparable overall survival with IO (n=509 [49%]) or other chemotherapeutic agents (n=530 [51%]), with a 24-month ΔRMST of only 0.
-
JAMA Oncol: Capecitabine maintenance therapy significantly improves survival in patients with metastatic nasopharyngeal carcinoma
Time of Update: 2022-03-05
In conclusion, for patients with metastatic nasopharyngeal carcinoma who achieved disease control after induction chemotherapy with capecitabine-containing regimen, capecitabine maintenance therapy can significantly prolong event-free survival with controllable side effects .
-
Gastric Cancer: D1/D2 and CRITICS study to explore the response and prognosis of different molecular subtypes of gastric cancer to neoadjuvant chemotherapy post hoc
Time of Update: 2022-03-05
In resectable gastric cancer, patients with the MSI-high subtype have a favorable prognosis compared with the EBV-/MSS subtype, both in those treated with surgery, and in those receiving perioperative chemotherapy (radiation) in treated patients .
-
Transl Lung Cancer Res: Efficacy of chemotherapy-antiangiogenic versus chemotherapy-immunotherapy combination therapy in patients with EGFR-mutant advanced NSCLC after failure of EGFR-TKI therapy
Time of Update: 2022-03-04
We screened patients with advanced NSCLC with EGFR mutations diagnosed between January 2015 and December 2020, who received chemotherapy-antiangiogenic or chemotherapy-immunotherapy combination therapy after EGFR-TKI resistance .
-
Clin Cancer Res: Efficacy of olaparib maintenance monotherapy in Asian patients with platinum-sensitive recurrent ovarian cancer
Time of Update: 2022-03-04
Olaparib monotherapy maintenance therapy significantly prolongs progression-free survival (PFS) compared with placebo in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC) .
This study is the first to evaluate the efficacy and tolerability of olaparib in Asian patients with platinum-sensitive recurrent ovarian cancer .
-
The new indication of "everolimus" was approved, and breast cancer treatment ushered in a new era of "endocrine +"
Time of Update: 2022-03-04
Good news for breast cancer patients: Novartis Afinitor® ( everolimus tablet) was recently approved by the State Drug Administration for a new indication, in combination with exemestane for the treatment of letrozole or anastrozole Hormone receptor-positive, epidermal growth factor receptor-2-negative, postmenopausal women with advanced breast cancer after failure .
-
Molecular Cell: Liu Ying's research group revealed a new mechanism of amino acid regulation of mTORC1 signaling pathway activity
Time of Update: 2022-03-04
On February 2, 2022, Liu Ying's research group from the Institute of Molecular Medicine, School of Future Technology, Peking University, Peking University-Tsinghua Life Science Joint Center, and Beijing Future Gene Diagnosis Advanced Innovation Center published an article entitled "E3 ligase RNF167 and deubiquitinase STAMBPL1 modulate mTOR and cancer progression”, reported the regulation mechanism of ubiquitin ligase RNF167 and deubiquitinase STAMBPL1 on mTORC1 and its important pathological significance .